Future Considerations for Front-line Treatment of DLBCL

Author(s):

David Miklos, MD,Haifaa Abdulhaq, MD

An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.

EP: 1.Emerging Updates in Front-line Treatment Approach of DLBCL

EP: 2.Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?

EP: 3.The Evolving First-line Treatment Approach for DLBCL

Now Viewing

EP: 4.Future Considerations for Front-line Treatment of DLBCL

EP: 5.Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease

EP: 6.Second-line Treatment Landscape in Relapsed/Refractory DLBCL

EP: 7.The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

EP: 8.Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

EP: 9.Real World Perspectives: Outcomes for CAR T-cell Therapy in Relapsed/Refractory DLBCL

Video content above is prompted by the following:

What studies or updates from ASH 2024 give new insights to subsequent treatment and safety management in the 1L setting.

Latest Conference Coverage

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

Next-Generation Sequencing Data Inform IO Treatment Sequencing in NSCLC

Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC

Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512